Marc Buyse

From MaRDI portal
Revision as of 20:09, 22 September 2023 by Import230922100944 (talk | contribs) (Created automatically from import230922100944)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Person:1029798

Available identifiers

zbMath Open buyse.marcWikidataQ38291268 ScholiaQ38291268MaRDI QIDQ1029798

List of research outcomes





PublicationDate of PublicationType
Individualized net benefit estimation and meta-analysis using generalized pairwise comparisons in \(N\)-of-1 trials2024-10-30Paper
Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: a simulation study2024-10-29Paper
Minimization in randomized clinical trials2024-06-23Paper
Generalized pairwise comparisons for censored data: an overview2024-06-05Paper
Correcting the bias of the net benefit estimator due to right‐censored observations2023-11-27Paper
A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons2023-11-23Paper
Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes2020-09-22Paper
Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials2018-08-14Paper
An information-theoretic approach for the evaluation of surrogate endpoints based on causal inference2016-10-12Paper
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials2016-03-14Paper
On the relationship between the causal‐inference and meta‐analytic paradigms for the validation of surrogate endpoints2016-01-22Paper
Predicting Treatment Effect from Surrogate Endpoints and Historical Trials: An Extrapolation Involving Probabilities of a Binary Outcome or Survival to a Specific Time2012-06-27Paper
Exploring and validating surrogate endpoints in colorectal cancer2009-07-13Paper
The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials2008-03-11Paper
A perspective on surrogate endpoints in controlled clinical trials2007-11-05Paper
Validation of a longitudinally measured surrogate marker for a time-to-event endpoint2007-09-11Paper
Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints2007-06-11Paper
Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points2007-05-30Paper
Criteria for the Validation of Surrogate Endpoints in Randomized Experiments2005-04-11Paper
Simplified hierarchical linear models for the evaluation of surrogate endpoints2003-10-29Paper
Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points2001-12-01Paper
The validation of surrogate endpoints in meta-analyses of randomized experiments2000-07-11Paper
https://portal.mardi4nfdi.de/entity/Q36875701983-01-01Paper

Research outcomes over time

This page was built for person: Marc Buyse